KR102588239B1 - A dispenser providing columnal formulation - Google Patents

Abstract

The present invention relates to a pillar-shaped dosage form. More specifically, the maximum width in the horizontal direction and the maximum height in the vertical direction of the pillar shape have constant values and ratios, and a certain amount is discharged at a time by a dispenser. As it has the following characteristics, it can be provided accurately and quickly according to the dosage that the user needs at one time. The formulation has a certain hardness, so there is a low possibility of damage within the dispenser when provided to the user, and it is easy to swallow when taking orally. has

Description

Dispenser that provides a column-shaped formulation {A DISPENSER PROVIDING COLUMNAL FORMULATION}

The present invention relates to a pillar-shaped dosage form. More specifically, the pillar-shaped dosage form has a maximum width in the horizontal direction and a maximum height in the vertical direction at constant values and ratios, and is dispensed in a certain amount at a time by a dispenser. Because it is characterized by being able to accurately and quickly provide the amount that the user needs at one time. In addition, the formulation has a certain hardness, so there is a low possibility of damage within the dispenser when provided to the user, and it is easy to swallow when taken orally.

Recently, interest in health has been steadily increasing, while the number of people taking nutritional supplements to resolve nutritional imbalances in busy lives is increasing.

There may be many things to consider when taking these nutritional supplements, but among them, the intake nutrients, intake dose, intake cycle, etc. are pointed out as important factors to be considered, and the above factors are related to the individual's health and nutritional intake status. However, the reality is that users who currently consume nutritional supplements sold on the market are consuming them without properly reflecting the three factors considered above - intake nutrients, intake dose, and intake cycle.

For example, users purchase commercial nutritional supplements and consume them as they are packaged. However, since each commercial nutritional supplement is not customized according to individual characteristics, one user may consume excessive amounts of one nutrient and consume other nutrients. Users may experience under-consumption of other daily nutrients.

Accordingly, there is a demand for related technologies that enable individuals to consume the nutrients they need in appropriate amounts according to their health and nutritional intake status.

Accordingly, the present inventors completed the present invention by confirming the effect of a pillar-shaped dosage form that can provide an appropriate intake considering the individual's situation. The dosage form has a low probability of breakage, can be consumed at an appropriate dosage for each individual, and is easy to swallow. did.

In order to solve the above problem, the present invention is a pillar-shaped formulation, wherein the maximum width in the horizontal direction and the maximum height in the vertical direction of the pillar shape have constant values and ratios, and a certain amount is discharged at a time by a dispenser. The purpose is to provide a pillar-shaped dosage form characterized by being.

In order to solve the above problems, the present invention is a pillar-shaped formulation, in which the maximum width in the horizontal direction and the maximum height in the vertical direction of the pillar shape have constant values and ratios, and a certain amount is discharged at one time by a dispenser. Provides a pillar-shaped dosage form characterized by being.

The present invention relates to a pillar-shaped dosage form. The maximum width in the horizontal direction and the maximum height in the vertical direction of the dosage form have constant values and ratios, and are characterized in that a certain amount is discharged at a time by a dispenser, so that the user can dispense the product once. It can be provided accurately and quickly according to the required dose, and at the same time, it has a certain hardness, which has the effect of lowering the possibility of damage within the dispenser when providing it to the user and making it easy to swallow when taking it orally.

Figure 1a shows a schematic diagram of the dosage form of the present invention when it has a cylindrical pillar shape.
Figure 1b shows a cross-section in the horizontal direction when the formulation of the present invention has a cylindrical pillar shape.
Figure 1c shows a schematic diagram of the dosage form of the present invention when the upper and lower surfaces of the dosage form are pillar-shaped with a radius of curvature.
Figure 2 shows a schematic diagram when the formulation of the present invention has a polygonal pillar shape.
Figure 3 shows a schematic diagram of the formulation of the present invention when it has a spherical shape.
Figure 4 is a diagram for explaining an example of a dispenser that dispenses a formulation according to the present invention.
Figure 5 is a diagram for explaining an example of a discharge unit in a dispenser that discharges a formulation according to the present invention.
FIG. 6 is a diagram for explaining an example of the frame in FIG. 5 in more detail.
Figure 7 is a diagram for explaining an example of a portion where a frame and a cartridge are combined.
FIG. 8 is a diagram for explaining an example of the discharge cap in FIG. 5 in more detail.
FIG. 9 is a diagram for explaining an example of the rotor in FIG. 5 in more detail.
FIG. 10 is a diagram for explaining a state in which the rotor, discharge cap, and frame in FIG. 5 are combined.
Figures 11A to 11E are diagrams for explaining a process in which a discharge unit discharges a formulation according to an example of the present invention.

The language used in this specification and patent claims should not be construed as limited to ordinary or dictionary meanings, and the principle is that the inventor can appropriately define the concept of terms in order to explain his or her invention in the best way. It must be interpreted as meaning and concept consistent with the technical idea of the invention. Therefore, the configurations such as the examples described in this specification are only one of the most preferred embodiments of the present invention and do not represent the entire technical idea of the present invention, and various equivalents and It should be understood that there may be variations.

Hereinafter, the present invention will be described in detail with reference to the drawings.

The present invention is a pillar-shaped dosage form, comprising: a main ingredient containing nutritional ingredients; and

A formulation containing an additive mixed with the main ingredient and having a pillar shape, wherein the maximum width of the cross-section in the horizontal direction of the pillar shape is 3 to 7 mm, and it has a height in the vertical direction intersecting the horizontal direction. The purpose is to provide a pillar-shaped dosage form.

In one embodiment of the present invention, the formulation of the present invention may be prepared as an oral preparation containing a main ingredient including nutritional ingredients and a pharmaceutically acceptable additive. The oral preparations include capsules, tablets, dry syrup-type preparations, syrup preparations, jelly-type preparations, or granules. In one embodiment, they may be formulated as tablets or capsules, but are not limited thereto.

As an oral preparation, tablets have the advantage of being able to precisely dose the drug, being convenient to handle and take, and being mass-produced at a low price. In addition, it is easy to correct bitterness, odor, and irritation through coating, and it is easy to control changes in drug elution and absorption patterns by molding, and has the advantage of reducing the breakage rate by increasing hardness.

The main ingredients included in the formulation according to the present invention may include water-soluble substances known in the art, specifically various vitamins, minerals, functional nutrients, amino acids, herbal ingredients, etc., and the ingredients are preferably water-soluble. It is not limited to ingredients or these.

“Main ingredient” as defined in the present invention refers to the main ingredient constituting the formulation of the present invention and is included in 50 to 99% by weight of the total formulation of the present invention, but is not limited thereto.

In one embodiment, the main ingredients included in the formulation of the present invention are magnesium (MgO), vitamin D, vitamin C, vitamin B1, vitamin B2, niacin, pantothenic acid, vitamin B6, biotin, folic acid, vitamin B12, vitamin E, iron, It may include, but is not limited to, any one or more selected from the group consisting of chromium, molybdenum, selenium, zinc, iodine, manganese, and copper.

Additionally, pharmaceutically acceptable additives included in the formulation of the present invention may be selected from the group consisting of pharmaceutically acceptable excipients, disintegrants, lubricants, anti-caking agents, coating agents, pigments, and mixtures thereof.

Excipients are additives that are safe and increase stability, and can be understood as substances used for the purpose of increasing the volume of solid formulations. Since it is difficult to tablet or fill capsules with only the main ingredient when manufacturing tablets, excipients can be added to create the shape of the product and can perform the function of increasing the hardness of the dosage form. In one embodiment, crystalline cellulose, maltodextrin, crystalline glucose, etc. may be used as excipients, but are not limited thereto.

The disintegrant refers to a composition that can be easily decomposed to maintain appropriate hardness of the oral preparation and ensure proper drug absorption upon oral administration. The disintegrant may be selected from one or two or more types commonly used in the manufacture of tablets, for example, mannitol (e.g., spray-dried mannitol), sorbitol, fructose, lactose, dextrose, xylitol, glucose, Lactose, white sugar, fructose, maltose, maltodextrin, erythritol, arabitol, crospovidone, croscarmellose sodium, microcrystalline cellulose (MCC), pregelatinized starch, starch and its derivatives, collidone, carboxymethyl Cellulose, carboxymethyl cellulose calcium (CMC), F-MELT (Fuji chemical), Ludiflash (BASF), etc. can be used. Specifically, the disintegrant may include any one or more of mannitol, Fmelt, sorbitol, xylitol, lactose, and pregelatinized starch.

In addition to the above composition, the oral preparation of the present invention contains various biologically inert ingredients for additional purposes such as stability, appearance, color, protection, maintenance, binding, performance improvement, manufacturing process improvement, or auxiliary release control of the active ingredient. can be used additionally.

These inert ingredients include diluents, sugars, sugar alcohols, polymers, colorants, flavoring agents, sweeteners, surfactants, lubricants, stabilizers, antioxidants, foaming agents, preservatives, disintegrants, buffering agents, bulking agents, diluents, and paraffin. , or wax, and one or more of these may be used. For example, the biologically inert ingredient may be a lubricant.

The lubricant has a glidant or anti-tacking effect, allowing tablets to be easily ejected from the compression die, eliminating problems such as adhesion during tablet compression, and preventing tablet breakage during tablet compression. Alternatively, the possibility of tablet layer separation phase occurring can be excluded. The lubricant is at least one selected from the group consisting of stearic acid, glyceryl behenate, glyceryl monostearate, magnesium stearate, calcium stearate, sodium stearyl fumarate, silicon dioxide, talc, and magnesium silicate. It may be magnesium stearate, and magnesium stearate may be preferably used.

Specifically, the use of the lubricant has the advantage of reducing the rate of defects due to tabletting failure as sticking does not occur during tablet compression, but if the content is used excessively, the standard range for the dissolution rate of the drug is not satisfied. Therefore, it is desirable to use it within a certain range.

Anti-caking agents are additives used to prevent food particles from agglomerating due to moisture absorption, and may be one or more selected from the group consisting of magnesium silicate, silicon dioxide, or talc, but are not limited thereto.

The coating agent can be added to increase the surface strength of the formulation of the present invention, and at this time, common polymers can be used, and specific examples include polyvinyl alcohol, hydroxyethylcellulose, hypromellose, polyvinylpyrrolidone, and A water-soluble polymer selected from the group consisting of mixtures; and hypromellose phthalate (HPMCP), polyvinylacetate (e.g., Colicoat® SR 30D), water-insoluble polymethacrylate copolymer [e.g., poly(ethylacrylate-methylmethacrylate) copolymer. polymers (e.g., Eudragit®NE30D), poly(ethylacrylate-methylmethacrylate-trimethylaminoethylmethacrylate chloride) copolymers (e.g., Eudragit®RSPO), etc.], ethylcellulose , cellulose esters, cellulose ethers, cellulose acylates, cellulose diacylates, cellulose triacylates, cellulose acetates, cellulose diacetates, cellulose triacetates, and mixtures thereof. It doesn't work.

The pigment may be selected from the group consisting of red iron oxide, yellow iron oxide, titanium oxide, blue No. 1, blue No. 2, and mixtures thereof. In the bead formulation of the present invention, a disintegrant and a lubricant are added based on the total weight of the formulation. The agent and anti-caking agent can be used in an amount ranging from 3 to 4% by weight, preferably 3.78 to 3.83% by weight, and the coating layer can be used in an amount of 0.5 to 0.9% by weight, preferably 0.7% by weight, and the disintegrant and lubricant , the mixing ratio of the anti-caking agent and the coating layer may be 4 to 5% by weight, preferably 4.48 to 4.53% by weight.

In terms of the shape of the dosage form of the present invention, the shape of the dosage form may generally be column-shaped, oval-shaped, triangular, almond-shaped, peanut-shaped, parallelogram, circular, pentagonal, hexagonal, spherical or trapezoid-shaped, but is preferably selected. may have a pillar shape.

In one embodiment, when the formulation of the present invention has a pillar shape, it may be any one of a polygonal pillar shape, a cylindrical pillar shape, an oval pillar shape, and a sphere, and the cross-section of the pillar shape may be square, pentagonal, hexagonal, octagonal, It may be circular or oval, but is not limited thereto.

A schematic diagram of the formulation of the present invention when it has a cylindrical pillar shape is shown in Figure 1, a schematic diagram when it has a polygonal pillar shape is shown in Figure 2, and a schematic diagram when it has a spherical shape is shown in Figure 3.

The horizontal cross-section of the pillar-shaped dosage form of the present invention may have a constant maximum width and a constant maximum height.

“Maximum width” defined in the present invention means the maximum width in the cross section of the column shape in the horizontal direction.

In addition, the “maximum height” defined in the present invention refers to the maximum height in the vertical direction of the pillar shape, including the height of the cylindrical part of the pillar and the sum of the heights of both ends if the upper and lower surfaces are hemispherical. means.

According to a preferred embodiment, when the pillar shape of the formulation of the present invention is a cylindrical pillar shape, when the maximum width of the pillar shape is 3 to 7 mm, the ratio of the maximum width in the horizontal direction and the maximum height in the vertical direction of the cylindrical pillar shape is 1:0.5 to 1:1.5, more preferably 1:0.8 to 1:1.2, and the maximum height is 3 to 7 mm within the ratio of the maximum width and maximum height in the vertical direction. .

In one embodiment, when the ratio of the maximum width in the horizontal direction and the maximum height in the vertical direction is 1:0.8 to 1:1.2, and the maximum width of the pillar shape is 4 mm, the maximum height is formed to be 3.2 to 4.8 mm. When the maximum width is 3.5 mm, the maximum height is 3 to 4.2 mm, and when the maximum width is 6.5 mm, the maximum height is 5.2 to 7 mm.

When the formulation of the present invention has the ratio of maximum width and maximum height as described above, stable discharge is possible even if it is seated not only in a direction parallel to the longitudinal direction of the formulation guide groove, but also in a direction crossing the length direction of the formulation guide groove, and the maximum width When the maximum height is 3 to 7 mm, it is easy to control the discharge amount and swallow, and has appropriate capacity resolution.

Specifically, as can be seen in Test Example 3 below, when the maximum width is 3 to 7 mm, the formulation has a hardness of 2.4 kp or more, has a dosage resolution of 35 to 100 mg, and is easy to swallow, so when taken orally. It was confirmed to be convenient to take. In addition, as in Test Example 4 below, it was possible to discharge the desired amount with almost no number error when discharging once, and it was confirmed that discharge was possible within 5 seconds, showing that the formulation of the present invention can be dispensed quickly and accurately using the dispenser. It was confirmed that

In addition, as shown in Test Example 5, when the ratio of the maximum width ( When the ratio of the maximum width and maximum height of the dosage form of the present invention was 1:0.5 to 1:1.5, it was confirmed that it was very easy to take because it had an appropriate maximum width and maximum height. As shown in Test Example 6, the maximum width of the dosage form ( When the ratio of It was confirmed that in the case of 1:0.8 to 1:1.2, discharge was possible within the desired error range, showing excellent discharge volume control.

In addition, the present invention is a spherical dosage form, the main ingredient containing nutritional ingredients; and an additive mixed with the main ingredient, wherein the maximum cross-sectional width in the horizontal direction of the spherical shape has a value equal to or different from the maximum height in the vertical direction intersecting the horizontal direction, and The purpose is to provide a pillar-shaped dosage form characterized by having a height in the vertical direction.

A schematic diagram of the formulation of the present invention when it has a spherical shape is shown in Figure 3.

According to one embodiment, when the dosage form of the present invention is spherical, the maximum width of the cross-section in the horizontal direction of the spherical dosage form has a value equal to or different from the maximum height in the vertical direction intersecting the horizontal direction, and the sphere-shaped dosage form has a maximum width in the horizontal direction. The maximum cross-sectional width of the shape in the horizontal direction may be 3 to 7 mm, but is not limited thereto.

According to a preferred embodiment when the dosage form of the present invention has a spherical shape, the ratio of the maximum width in the horizontal direction and the maximum height in the vertical direction of the spherical shape is 1 when the maximum width of the spherical shape is 3 to 7 mm: It is 0.5 to 1:1.5, more preferably 1:0.8 to 1:1.2, and the maximum height in the vertical direction is 3 to 7 mm.

The dosage form of the present invention can be manufactured into tablets by compressing a mixture or granule of a pharmacologically active ingredient and a pharmaceutically acceptable additive in a tablet press, wherein the tablet pressure of the tablet press, the presence or absence of a coating layer, the main ingredient and the additive substance are adjusted. It can have various hardnesses depending on the type and content ratio.

The hardness of tablets is related to the characteristics of the granulation process, and generally, the higher the compression pressure, the higher the hardness. When slow dissolution is required, the hardness is intentionally increased, and when rapid release is required, the hardness of the tablet is manufactured to be low. In general, tablets must have sufficient hardness not to break during routine handling such as packaging and transportation, but at the same time, they must have appropriate hardness so that they disintegrate properly and are easily dissolved after ingestion.

According to a preferred embodiment of the invention, the maximum width of the dosage form of the invention as described above is 3 to 7 mm, preferably 3 to 5 mm, more preferably 3.5 mm, and the difference between the maximum width and the maximum height is The ratio is preferably 1:0.5 to 1:1.5, more preferably 1:0.8 to 1:1.2, where the maximum height is 3 to 7 mm, and the hardness of the formulation having the above maximum width and maximum height is 2.4 to 35.0. It has a hardness value of kp (kilopond), preferably 2.4 to 20 kp, more preferably 2.4 to 6 kp.

In one embodiment, when the hardness of the formulation of the present invention is 35 kp or less, the disintegration time is within 1 hour, when the hardness is 20 kp or less, the disintegration time is within 20 minutes, and when the hardness is 6 kp or less, the disintegration time is within 5 minutes.

Specifically, as can be seen in Test Example 1 below, when the hardness of the formulation of the present invention was 2.1 kp or less, damage to some of the formulation was confirmed within the dispenser, and when the hardness was 2.4 and 2.7 kp, there was some dusting, but the shape of the formulation was changed. It was observed that maintenance was possible, and when the hardness was 3.0 kp or more, it was confirmed that the formulation maintained its pillar shape excellently without breakage or dusting within the dispenser.

In addition, as shown in Test Example 2, when the hardness of the formulation of the present invention was 40 kp or more, it did not disintegrate within the appropriate time. For hardnesses between 25 and 35 kp, it disintegrated within 1 hour, and at hardnesses between 7 and 20 kp, it disintegrated within 20 minutes. It was confirmed that when the hardness of the formulation was 3 to 6 kp, it disintegrated within 5 minutes and had an appropriate disintegration time while maintaining the cylindrical column shape inside the dispenser as in Test Example 1.

Accordingly, when the hardness of the formulation of the present invention is 2.4 to 6 kp, it was confirmed that the formulation was not damaged even when the formulation was formed and used after being packaged and discharged from the dispenser, so it was confirmed that it could be used without damage to the formulation even when discharged from the dispenser and used. At the same time, it was confirmed that it dissolved at an appropriate disintegration time.

If the pillar shape of the dosage form of the present invention is a cylindrical pillar shape, for example, it may be a cylindrical shape with both ends in a hemispherical shape.

A schematic diagram of the dosage form of the present invention when it has a cylindrical pillar shape is shown in Figure 1.

The “radius of curvature” defined in the present invention refers to the radius of curvature of the curved surface with respect to the vertical direction of the upper and lower surfaces when both ends of the cylindrical pillar shape are hemispherical, as shown in FIG. 1C.

According to a preferred embodiment of the present invention, when the hemispherical shape is cylindrical with both ends, the ratio of the maximum width of the pillar and the radius of curvature may be 1:0.6 to 1:1.8.

Specifically, as can be seen in Test Example 7 below, when the ratio of the maximum width to the radius of curvature is 1:0.6 to 1:1.8, it is easy to swallow, and the hardness is measured at 2.4 kp, so it is possible to form a dosage form, but there is a possibility of breakage. was confirmed to be low, and control of the number of discharges from the dispenser was also confirmed to be excellent.

Additionally, the column-shaped formulation of the present invention may be provided in the form of beads from a dispenser.

The bead formulation can be prepared as an oral formulation. The oral preparations include capsules, tablets, dry syrup-type preparations, syrup preparations, jelly-type preparations, or granules. In one embodiment, they may be formulated as tablets or capsules, but are not limited thereto.

Additionally, the formulation of the present invention can be dispensed from a dispenser, and can be provided accurately and quickly according to the dosage required by the user at one time.

The formulation of the present invention may be discharged at a rate of 3 to 7 beads per second from each bead cartridge of the dispenser, for example, 25 to 250 beads may be discharged at a time from the dispenser, and in this case, the one discharge time may take 1 to 10 seconds. However, it is not limited to this.

Specifically, as can be seen in Test Example 4 below, when the maximum width of the formulation of the present invention is 3.5 to 7 mm, there is almost no number error during discharge, so it is possible to discharge the desired amount, and at the same time, the discharge time is within 5 seconds. It was confirmed that it was possible to quickly and accurately dispense the formulation of the present invention using the dispenser.

Hereinafter, the present invention will be described in detail through embodiments of the present invention with reference to the attached drawings. However, the following implementation examples are provided as examples of the present invention, and if it is judged that a detailed description of a technology or configuration well known to those skilled in the art may unnecessarily obscure the gist of the present invention, the detailed description may be omitted. , the present invention is not limited thereby. The present invention is capable of various modifications and applications within the description of the patent claims described below and the scope of equivalents interpreted therefrom.

In addition, the terminology used in this specification is a term used to appropriately express preferred embodiments of the present invention, and may vary depending on the intention of the user or operator or the customs of the field to which the present invention belongs. Therefore, definitions of these terms should be made based on the content throughout this specification. Throughout the specification, when it is said that a part “includes” a certain element, this means that it may further include other elements rather than excluding other elements, unless specifically stated to the contrary.

Hereinafter, unless otherwise specified, % means weight %, which represents the ratio of the weight of the ingredient in question to the total weight of the formulation.

Example 1. Fabrication of bead formulation

The pillar-shaped dosage form of the present invention was prepared as follows.

Granules are manufactured by mixing the main ingredient and additives, and then the granules are filled into a cylinder groove having a column-shaped groove, and the upper surface of the cylinder groove is compressed so that the hardness of the formulation is within a predetermined range. Tablets according to each width were compressed.

Hereinafter, a cylindrical pillar-shaped dosage form with a circular horizontal cross-section will be described as an example, but the present invention is not limited thereto.

That is, the formulation of the present invention is applicable not only when the horizontal cross-section of a polygonal pillar, cylindrical pillar or sphere is circular, but also when the horizontal cross-section of the polygonal pillar shape is square, pentagonal, hexagonal, octagonal or cylindrical pillar. If the cross-section is oval or spherical, it can also be included when the cross-section is circular.

Test Example 1. Measurement of the degree of damage of the formulation inside the dispenser according to the hardness of the cylindrical column-shaped formulation.

The degree of damage in the dispenser according to the hardness of the formulation of the present invention was measured in the following manner.

A score of 1 to 4 points was given depending on the degree of damage; 1 point if most of the formulation was damaged in the dispenser by more than 90% and the original shape could not be maintained; 90 if some of the formulation was damaged in the dispenser and the damage rate was 20% or more. 2 points if less than %, 3 points if there is some dusting in the dispenser but the shape of most formulations can be maintained, and 4 points if the shape of the pillar is maintained well without dusting in the dispenser. The results of this experiment are given. is shown below.

Hardness (kp) breakage rate 7.0 or higher 4 6.5 4 6.0 4 5.5 4 5.0 4 4.5 4 4.0 4 3.5 4 3.0 4 2.7 3 2.4 3 2.1 2 1.8 2 1.5 or less One

As a result, as shown in Table 1, when the hardness of the formulation of the present invention was 2.1 kp or less, some damage to the formulation was confirmed within the dispenser, and when the hardness was 2.4 and 2.7 kp, there was some dusting, but the shape of the formulation was confirmed to be maintained. It was observed that when the hardness was above 3.0 kp, it was confirmed that the formulation maintained its pillar shape excellently without breakage or dusting within the dispenser.

Test Example 2. Measurement of disintegration time of the formulation according to the hardness of the cylindrical column-shaped formulation

A disintegration test was performed to measure the disintegration time according to the hardness of the formulation of the present invention.

The disintegration test was performed in one solution (pH 1.2) and purified water at a temperature of 37°C according to the Korean Pharmacopoeia to measure the disintegration time of the formulation of the present invention, and the results of this experiment are shown below.

Hardness (kp) Disintegration time 45.0 Does not disintegrate 40.0 Does not disintegrate 35.0 in 1 hour 30.0 in 1 hour 25.0 in 1 hour 20.0 Within 20 minutes 15.0 Within 20 minutes 10.0 Within 20 minutes 7.5 Within 20 minutes 7.0 Within 20 minutes 6.0 Within 5 minutes 5.0 Within 5 minutes 4.0 Within 5 minutes 3.0 or less Within 5 minutes

As a result, as shown in Table 2, when the hardness of the formulation of the present invention was 40 kp or more, it did not disintegrate within the appropriate time, at hardnesses between 25 and 35 kp, it disintegrated within 1 hour, and at hardnesses between 7 and 20 kp, it disintegrated within 20 kp. It was disintegrated within minutes, and when the hardness of the formulation was 3 to 6 kp, it was found to have an appropriate disintegration time as it disintegrated within 5 minutes while maintaining the cylindrical column shape inside the dispenser as in Test Example 1. Therefore, it was confirmed that when the hardness of the formulation of the present invention is 3 to 6 kp, rapid disintegration occurs and rapid absorption is possible.

Test Example 3. Measurement of hardness formation, capacity resolution, and degree of necking according to the maximum width of the cylindrical column shape.

The hardness formation, capacity resolution, and throat swallowing degree according to the maximum width of the formulation of the present invention were measured.

In the case of swallowing, a convenience test was conducted on 10 people for each maximum width and length of the dosage form of the present invention to determine the ease of oral administration. After orally taking 100 tablets of the dosage form of the present invention for each maximum width and length, the degree to which the dosage form is swallowed is rated as follows: 1: very difficult / 2: difficult / 3: normal / 4: easy / 5: very easy. After calculating the average value by scoring, the range of each average value was written as 1 to 2: very difficult / 2 to 3: difficult / 3 to 4: easy / 4 to 5: very easy. The results of this experiment are shown below. It was.

Maximum width (mm) Hardness (kp) capacity resolution About to swallow 10.0 2.4 and above More than 100 mg very difficult 9.5 2.4 and above More than 100 mg very difficult 9.0 2.4 and above More than 100 mg very difficult 8.5 2.4 and above More than 100 mg difficult 8.0 2.4 and above More than 100 mg difficult 7.5 2.4 and above More than 100 mg difficult 7.0 2.4 and above 75 to 100 mg dragon 6.5 2.4 and above 75 to 100 mg dragon 6.0 2.4 and above 50 to 75 mg dragon 5.5 2.4 and above 50 to 75 mg dragon 5.0 2.4 and above 50 to 75 mg very easy 4.5 2.4 and above 40 to 50 mg very easy 4.0 2.4 and above 40 to 50 mg very easy 3.5 2.4 and above 40 to 50 mg very easy 3.0 2.4 and above 35 to 40 mg very easy 2.5 2.4 and above 35 to 40 mg very easy 2.0 less than 2.4 Less than 30 mg very easy 1.5 less than 2.4 Less than 30 mg very easy 1.0 No bead formation Less than 30 mg very easy 0.5 No bead formation Less than 30 mg very easy

As a result, as shown in Table 3, when the maximum width was less than 1 mm, the formulation was not formed, and when it was 2 mm, the hardness of the formulation was measured to be less than 2.4 kp, and when it had the corresponding hardness, as shown in Test Examples 1 and 2. Breakage of the formulation was measured within the dispenser, confirming that appropriate hardness was not formed.

In addition, when the maximum width is 2.5 mm or more, the hardness of the formulation is measured to be more than 2.4 kp, and at the same time as the formulation is formed, as shown in Test Examples 1 and 2, the formulation is not damaged even when discharged from the packaging and dispenser and used. It was confirmed that it had a hardness that could be used without damage to the formulation.

In terms of dosage resolution, it was confirmed that it exceeded 100 mg when the maximum width was 7.5 mm or more. In terms of swallowing, it was found that it was very difficult to swallow when taking oral medication when the maximum width was 9 mm or more. It was easy to take when it was 7 mm or more, and it was easy to swallow when the maximum width was 9 mm or more. In the case below, it was found to be very easy. This is believed to be because the smaller the maximum width, the smaller the size of the dosage form, which reduces discomfort when swallowing.

Test Example 4. Measurement of discharge volume control degree in dispenser according to maximum width of cylindrical column shape

The discharge amount of the formulation of the present invention from the dispenser was measured in the following manner.

In the case of the degree of discharge volume control, the average discharge volume after 5 repeated discharges is based on the discharge amount of 100 grains from the cartridge at one time. Depending on the error range of the discharge number, 1: discharge volume cannot be controlled / 2: 85 to 90 grains discharged and 110 to 115 grains discharged / Scores were given as follows: 3: 91 to 96 tablets discharged and 104 to 109 tablets dispensed / 4: 97 tablets to 103 tablets dispensed.

In the case of ejection time, the results of simulating the average time required to eject 1 g of formulation from the cartridge are shown below.

maximum width Degree of discharge volume control discharge time 10.0 4 Within 5 seconds 9.5 4 Within 5 seconds 9.0 4 Within 5 seconds 8.5 4 Within 5 seconds 8.0 4 Within 5 seconds 7.5 4 Within 5 seconds 7.0 4 Within 5 seconds 6.5 4 Within 5 seconds 6.0 4 Within 5 seconds 5.5 4 Within 5 seconds 5.0 4 Within 5 seconds 4.5 4 Within 5 seconds 4.0 4 Within 5 seconds 3.5 4 Within 5 seconds 3.0 3 >5 seconds 2.5 2 >8 seconds 2.0 2 >8 seconds 1.5 2 Discharge not possible 1.0 One Discharge not possible 0.5 One Discharge not possible

As a result, as shown in Table 4, when the maximum width of the formulation of the present invention was 0.5 and 1 mm, it was impossible to control the number of bead formulations discharged at one time from the dispenser, but when the maximum width was 3.5 to 7 mm, there was a number error during discharge. It was confirmed that it was possible to discharge the desired amount as there was almost no discharge, and at the same time, the discharge time was possible within 5 seconds. It was confirmed that the formulation of the present invention can be discharged quickly and accurately using the dispenser.

Test Example 5. Measurement of throat swallowing during oral administration according to the maximum width and maximum height ratio of the cylindrical column shape

The degree of neck flipping according to the maximum width (X) and maximum height (Y) ratio of the present invention was measured.

In the case of swallowing, a convenience test was conducted on 10 people for each maximum width and length to determine the ease of oral administration. After orally taking 100 tablets of the dosage form of the present invention for each maximum width and length, the degree to which the dosage form is swallowed is rated as follows: 1: very difficult / 2: difficult / 3: normal / 4: easy / 5: very easy. After calculating the average value by scoring, the range of each average value was written as 1 to 2: very difficult / 2 to 3: difficult / 3 to 4: easy / 4 to 5: very easy. The results of this experiment are shown below. It was.

X:Y About to swallow 1:1.6 difficult 1:1.5 difficult 1:1.4 dragon 1:1.3 dragon 1:1.2 very easy 1:1.1 very easy 1:1.0 very easy 1:0.9 very easy 1:0.8 very easy 1:0.7 dragon 1:0.6 dragon 1:0.5 difficult 1:0.4 very difficult 1:0.3 very difficult

As a result, as shown in Table 5, it was confirmed that when the ratio of the maximum width ( It was confirmed that when the ratio of the maximum width and maximum height of the dosage form of the present invention was 1:0.5 to 1:1.5, it had an appropriate maximum width and maximum height, making it very easy to take.

Test Example 6. Degree of discharge control according to the maximum width and maximum height ratio of the cylindrical column shape

The degree of discharge control in the dispenser was measured according to the maximum width (X) and maximum height (Y) ratio of the formulation of the present invention.

In the case of the degree of discharge volume control, the average discharge volume after 5 repeated discharges is based on the discharge amount of 100 grains from the dispenser at one time. Depending on the error range of the discharge number, 1: Discharge volume cannot be controlled / 2: 85 to 90 grains discharged and 110 to 115 grains discharged / The results of this experiment are shown below by assigning scores as 3: 91 to 96 eggs discharged and 104 to 109 eggs discharged / 4: 97 eggs to 103 eggs discharged.

X : Y Discharge volume control degree 1:1.6 One 1:1.5 One 1:1.4 2 1:1.3 2 1:1.2 3 1:1.1 4 1:1.0 4 1:0.9 4 1:0.8 3 1:0.7 2 1:0.6 2 1:0.5 One 1:0.4 One 1:0.3 One

As a result, as shown in Table 6, discharge from the dispenser was impossible when the ratio of the maximum width (X) and maximum height (Y) of the formulation of the present invention was 1:0.3 to 1:0.5, and 1:0.6 and 1:0.5. In the case of 0.7, discharge was possible, but discharge within the desired error range was not possible. In addition, when the ratio of the maximum width (X) and maximum height (Y) of the formulation was 1:0.8 to 1:1.2, discharge was possible within the desired error range, showing excellent discharge volume control.

Test Example 7. Measurement of the degree of necking, hardness formation, and discharge control according to the maximum width of the cylindrical column shape and the radius of curvature of both ends of the column.

The maximum width (

The degree of swallowing and the hardness of the formulation were measured as in Test Example 3, and the degree of discharge control from the dispenser was measured in the same way as in Test Example 4, and the results of this experiment are shown below.

X : r About to swallow Hardness Discharge volume control 1:2.4 dragon 2.4 kp or more 2 1:2.2 dragon 2.4 kp or more 2 1:2.0 dragon 2.4 kp or more 2 1:1.8 very easy 2.4 kp or more 3 1: 1.6 very easy 2.4 kp or more 4 1: 1.4 very easy 2.4 kp or more 4 1: 1.2 very easy 2.4 kp or more 4 1:1.0 very easy 2.4 kp or more 4 1:0.8 very easy 2.4 kp or more 3 1:0.6 very easy 2.4 kp or more One 1:0.4 dragon Less than 2 kp One 1:0.2 difficult Less than 2 kp One

As a result, as shown in Table 7, when the ratio of the maximum width and the radius of curvature of both ends of the pillar is 1:0.6 to 1:1.8, it is easy to swallow, and the hardness is measured to be more than 2.4 kp, so it is possible to form a dosage form, but there is a possibility of breakage. was confirmed to be low, and control of the number of discharges from the dispenser was also confirmed to be excellent.

On the other hand, at a ratio of 1:2.0 or more, there was a difference from the desired number in controlling the discharge number, and at a ratio of 1:0.6 or less, it was confirmed that it did not have sufficient hardness to form a formulation.

Figure 4 is a diagram for explaining an example of a dispenser 1 that dispenses a formulation according to the present invention.

4 and below, for convenience of explanation, the direction toward the front or rear of the dispenser 1 with respect to the dispenser 1 is referred to as the first direction (x), and the direction horizontally intersecting the first direction (x) is referred to as the second direction. The direction perpendicular to the direction (y), the first and second directions is called the third direction (z).

Here, Figure 4 (a) shows the overall appearance of the dispenser 1, Figure 4 (b) shows an example of opening and closing the upper cover 50 in the dispenser 1, and Figure 4 (c) shows an example of inserting the cartridge unit 60 into some of the plurality of storage units 10 provided in the dispenser 1.

As shown in (a) of FIG. 4, an example of a dispenser 1 that dispenses a formulation according to the present invention includes a receiving portion 10, a main body 20, a device terminal 30, and a stand 40. can do.

The storage unit 10 is located on the front side in the first direction (x) of the dispenser 1, the main body 20 is located on the back side in the first direction (x) of the dispenser 1, and the device terminal 30 is Located at the top of the dispenser 1, the stand 40 may be located at the bottom of the storage unit 10.

The dispenser 1 can determine the types of formulations containing different nutritional ingredients and the number of each formulation according to the user's real-time physical condition and provide them to the user.

The receiving portion 10 is located on the front side of the dispenser 1, is provided long in the third direction (z), and has an overall outer shape that may include a curved surface (e.g., circular), as shown in (b) of FIG. 4 As described above, a plurality of cartridge units 60 can be accommodated.

As shown in (c) of FIG. 4, each of the plurality of cartridge parts 60 may be provided in a cylindrical shape having an overall length.

Each of the plurality of cartridge units 60 may include a cartridge 70 in which the formulation is stored and a discharge unit 80 coupled to the cartridge 70 to discharge the formulation.

Each of the plurality of cartridges 70 can store formulations containing different types of nutritional ingredients. Each of these cartridge units 60 may be formed by combining one discharge unit 80 with one cartridge 70. Each discharge unit 80 can be controlled independently.

The upper part of the receiving part 10 may be opened as shown in (b) of FIG. 4, and for this purpose, an upper cover 50 may be provided on the upper part of the receiving part 10. One end of the upper cover 50 is hinged to a part of the main body 20 and can be opened by the user, as shown in (b) of FIG. 4.

As shown in (c) of FIG. 4, the storage unit 10 may be provided with a plurality of storage grooves 11 long in the third direction (z) in which a plurality of cartridge parts 60 can be stored, and a plurality of storage grooves 11 in which a plurality of cartridge parts 60 can be accommodated. The storage groove 11 may be arranged radially with respect to the center of the storage unit 10, as shown in (b) and (c) of Figures 4. For example, the plurality of storage grooves 11 may be arranged in a circle with the cartridge portion 60 located at the same distance from the center.

Although FIG. 4 shows an example where the number of storage grooves 11 is 8, the number of storage grooves 11 may be more or less than 8.

Accordingly, when the formulation is discharged from each cartridge unit 60 inserted into each of the plurality of storage grooves 11, the time until each formulation is discharged toward the pedestal 40, which is outside of the dispenser 1, is equalized. You can.

As shown in (c) of FIG. 4, a storage guide groove 12 may be provided on one side of each storage groove 11 to guide the insertion direction of the cartridge unit 60. Such a storage guide groove 12 may have a shape in which the storage groove 11 protrudes toward the center of the storage portion 10.

Corresponding to the storage guide groove 12, a storage guide protrusion 81 may be further provided on one side of the discharge unit 80 in each cartridge unit 60. Such storage guide protrusion 81 may have a shape in which a portion of the discharge unit 80 protrudes outward, and when the cartridge portion 60 is inserted into the storage guide groove 12, the storage guide protrusion 81 It can be inserted into the storage guide groove (12).

An indicator lamp 90 may be provided at the center of the storage unit 10 to indicate whether each cartridge unit 60 is correctly mounted in each storage groove 11.

For example, the display lamp 90 may indicate whether each cartridge unit 60 is properly inserted into each storage groove 11. To this end, although not shown in the drawings, for example, a switch may be provided on the bottom of each storage groove 11 to turn on or off the display lamp 90 when the cartridge unit 60 is inserted. there is.

As the number of cartridge units 60 inserted into the plurality of storage grooves 11 increases, the number of formulations discharged per unit time from the dispenser 1 may increase. For example, each cartridge unit 60 can discharge 5 to 10 or more tablets per second at high speed, and as the number of cartridge units 60 inserted into the dispenser 1 increases, the dispenser 1 discharges more. The number of formulations per second can be increased. For example, the number of formulations discharged at one time from the dispenser 1 may be between 25 and 250.

The device terminal 30 generally controls the operation of the dispenser 1 and can display a menu for user settings on the touch screen. Specifically, the dispenser 1 can control the number of formulations discharged from each cartridge unit 60 by receiving a touch input from the user.

The main body 20 may be equipped with a refrigeration device for refrigerating the storage unit 10 where the plurality of cartridge units 60 are located. Although not shown in FIG. 4, a heat sink and a heat sink (fan) included in the refrigeration device ) can be provided.

Figure 5 is a diagram for explaining an example of the cartridge portion 60 in the dispenser 1 that discharges the formulation according to the present invention.

5 and below, for convenience of explanation, when the rotor unit 300 rotates toward the direction in which the formulation is discharged, it is referred to as normal rotation, and when the rotor section 300 rotates in the opposite direction to the forward rotation direction in which the formulation is discharged, it is referred to as reverse rotation. It is called rotation.

As shown in FIG. 5, the cartridge unit 60 according to an example of the present invention may include a cartridge 70 and a discharge unit 80.

The inlet of the cartridge 70 may be coupled to the discharge unit 80 with the inlet facing downward.

The discharge unit 80 may include a frame 100, a rotor unit 300, and a discharge cap 200. The frame 100, the rotor unit 300, and the discharge cap 200 may be sequentially coupled along the longitudinal direction of the cartridge unit 60.

The frame 100 has an overall cylindrical shape having a length in the longitudinal direction (z) of the cartridge 70 and forms the outer shape of the discharge unit 80, and has a first section that penetrates in the longitudinal direction (z) of the cartridge 70. It may include an opening 100A and a second opening 100B.

The first opening 100A has a circular inner surface and can be coupled to the cartridge 70. The second opening 100B is located in the opposite direction of the first opening 100A in the frame 100, and has at least a portion of the inner surface formed in a circular shape so that it can be coupled to the rotor unit 300 and the discharge cap 200. . A storage guide protrusion 81 may be located on the outer surface of the frame 100 adjacent to the second opening 100B. This frame 100 will be described in more detail below in FIG. 6.

The discharge cap 200 may be provided with a rotating hole 204 penetrating in the longitudinal direction (z) of the cartridge 70 at its center, and may be provided with a disk-shaped surface outside the rotating hole 204. A discharge port 201 penetrating in the longitudinal direction (z) of the cartridge 70 may be formed on at least some of the disk-shaped surfaces.

The discharge cap 200 may function to discharge the formulation to the outside of the cartridge unit 60. To this end, the discharge cap 200 may include a discharge pipe 202 that extends from the lower part of the discharge port 201 in the longitudinal direction (z) of the cartridge 70 and guides the discharge of the formulation.

The discharge cap 200 may be provided with a memory chip storage portion 10 that protrudes outward from a portion of the disc-shaped surface. This discharge cap 200 will be described in more detail below in FIG. 8.

The rotor unit 300 may function to move some of the plurality of formulations located in the frame 100 toward the discharge port 201 of the discharge cap 200. To this end, the rotor unit 300 has an overall circular surface and may include a formulation guide groove 340 and a drive shaft groove 301.

The formulation guide groove 340 has a shape that opens a portion of a circularly formed surface toward the outside from the center of the rotor unit 300, and the discharge cap 200 passes through the opened portion of the formulation guide groove 340. Part of it may be exposed. The formulation guiding groove 340 can load some of the formulations among the plurality of formulations positioned on the circularly formed surface so that they are arranged in a line in the formulation guiding groove 340.

The drive shaft groove 301 is located below the center portion of the rotor unit 300 and may protrude in the direction of the rotation hole 204 of the discharge cap 200. The drive shaft groove 301 may be coupled to the rotation shaft (not shown) of a drive motor (not shown) that drives the discharge unit 80.

This rotor unit 300 will be described in more detail below in FIG. 9.

The drive shaft groove 301 of the rotor unit 300 is inserted into the rotation hole 204 of the discharge cap 200, so that the rotor unit 300 can be rotatably coupled to the discharge cap 200. And the discharge cap 200 may be fixedly coupled to the second opening 100B of the frame 100. Here, the memory chip storage portion 10 of the discharge cap 200 may be coupled to the storage guide protrusion 81 of the frame 100.

Accordingly, while the rotor unit 300 rotates within the frame 100, a plurality of formulations located in the internal space of the frame 100 may be loaded into the formulation guidance groove 340 of the rotor unit 300. Thereafter, as the rotor unit 300 continues to rotate forward, the plurality of formulations loaded into the formulation guidance groove 340 may move along the forward rotation direction of the rotor section 300. At this time, when the outer formulation located on the outermost side of the formulation guide groove 340 is located on the discharge port 201 of the discharge cap 200, the formulation can be discharged through the discharge pipe 202.

The dispenser 1 of the present invention has a structure that sequentially discharges the formulation as the rotor unit 300 rotates with a plurality of formulations arranged in a row in the formulation guide groove 340, thereby dispensing the formulation at high speed. It can be discharged.

Hereinafter, the above-described discharge unit 80 will be described in more detail.

FIG. 6 is a diagram for explaining an example of the frame 100 in FIG. 5 in more detail, and FIG. 7 is a diagram for explaining an example in which the frame 100 and the cartridge 70 are combined.

Figure 6 (a) is a perspective view of the frame 100 looking down from the first opening 100A, and Figure 6 (b) is a cross-section of the frame 100 along the S1-S1 line in Figure 6 (a). It is a cross-sectional view showing, and Figures 6 (c) and (d) are views of the frame 100 as seen from the second opening (100B).

As shown in FIG. 6, the frame 100 may include an outer wall 110, an inner wall 120, a connecting portion 130, a separating rib 140, a blocking rib 150, and a storage guide protrusion 81. there is. Here, the storage guide protrusion 81 is the same as described above.

The outer wall 110 extends in the longitudinal direction (z) of the cartridge 70 and may form the outer shape of the frame 100. The inner wall 120 is formed on the inside of the outer wall 110 and spaced apart from the outer wall 110, and a plurality of formulations may be located in the space formed by the inner wall 120.

The inlet of the cartridge 70 may be coupled to the outer wall 110 on the first opening 100A side. For example, in Figure 6, a plurality of threads are formed on the inner surface of the outer wall 110, and the inlet of the cartridge 70 is screwed to the threads of the outer wall 110, as shown in Figure 7, the cartridge 70 and the frame ( 100) can be combined.

When the cartridge 70 and the first opening 100A of the frame 100 are coupled, the end of the inlet of the cartridge 70 may contact the end of the inner wall 120, as shown in FIG. 7 . Accordingly, the plurality of dosage forms stored in the cartridge 70 can naturally be moved to the space formed by the inner wall 120 of the frame 100.

The blocking rib 150 may be provided to protrude and extend from the end of the inner wall 120 toward the first opening 100A in the direction toward the cartridge 70. There may be a plurality of blocking ribs 150 as shown in FIG. 6, and the distance between the plurality of blocking ribs 150 may narrow as it approaches the first opening 100A. Accordingly, it is possible to prevent a preservative (eg, silica gel foam) that is stored together with a plurality of formulations in the cartridge 70 and has a larger volume than the formulation from entering the space within the inner wall 120 of the frame 100.

The connection portion 130 may connect the inner wall 120 and the outer wall 110 to each other at the second opening 100B of the frame 100. Here, as shown in (b) of FIG. 6, the connection portion 130 facing the second opening 100B may have an inclined surface.

As shown in (b), (c), and (d) of FIG. 6, the separation rib 140 may be located at the lower part of the connection portion 130 facing the second opening 100B, and the connection portion 130 ), protrudes toward the second opening 100B, and may be formed to extend in the forward rotation direction. More specifically, the separation rib 140 may be located adjacent to the discharge port 201 in the forward rotation direction.

For example, when the rotor unit 300 moves in a forward rotation direction, the starting end (140S) of the separating rib 140 may be located before the discharge port 201, and the ending end (140E) of the separating rib 140 may be located before the discharge port 201. It can be located overlapping with (201). Here, as shown in (d) of FIG. 6, the longitudinal end 140E of the separating rib 140 may overlap with more than 1/2 of the rotational direction length of the discharge port 201.

Additionally, the protruding height 140H2 of the terminal end 140E of the separating rib 140 may be greater than the protruding height 140H1 of the starting end 140S of the separating rib 140. For example, as shown in (b) of FIG. 6, the protrusion height may gradually increase from the starting end 140S of the separation rib 140 as it progresses in the forward rotation direction. Accordingly, as shown in (b) of FIG. 6, an inclined surface whose protrusion height gradually increases may be provided at the starting end 140S of the separation rib 140.

The separation rib 140 assists high-speed discharge of the formulation and can minimize jamming caused by a plurality of formulations at the entrance of the discharge port 201. The function of the separation rib 140 is explained in detail in FIGS. 11A to 11E.

FIG. 8 is a diagram for explaining an example of the discharge cap 200 in FIG. 5 in more detail.

Figure 8 (a) is a perspective view of the discharge cap 200, and Figure 8 (b) shows a cross-section of the discharge cap 200 along the line S2-S2 in Figure 8 (a). (c) in Figure 8 is a view of the discharge cap 200 from the memory chip storage unit 10, and (d) in Figure 8 is a view looking down at the discharge cap 200 from above.

As shown in FIG. 8, the discharge cap 200 includes a rotating hole 204, a first discharge rail 210, a second discharge rail 220, a plurality of guide protrusions 230, a discharge port 201, and a discharge It may include a tube 202 and a memory chip storage unit 10.

Here, description of the same parts as described above regarding the rotation hole 204, discharge port 201, discharge pipe 202, and memory chip storage unit 10 will be omitted.

The first discharge rail 210 may be provided on the outer periphery of the rotation hole 204 in a disk shape including a plane perpendicular to the direction of the rotation axis of the rotation hole 204. A portion of the first discharge rail 210 may be exposed to the space formed by the inner wall 120 of the frame 100 through the formulation guide groove 340 of the rotor unit 300. The formulation loaded inside the formulation guidance groove 340 may be moved along the first discharge rail 210.

The second discharge rail 220 may be located along the outer periphery of the first discharge rail 210, and the discharge port 201 may be located on the second discharge rail 220. Specifically, the discharge port 201 may be located adjacent to the memory chip storage unit 10 on the second discharge rail 220.

The second discharge rail 220 may include a first inclined surface 221 inclined outward from the first discharge rail 210. A portion of the second discharge rail 220 may be exposed to the space formed by the connection portion 130 of the frame 100 through the formulation guide groove 340 of the rotor portion 300. The formulation loaded on the outside of the formulation guide groove 340 can move along the second discharge rail 220, and if the formulation is located on the discharge port 201 while moving, it can be discharged to the outside through the discharge port 201. there is.

The first inclined surface 221 of the second discharge rail 220 may be formed parallel to the inclined surface of the connection portion 130 of the frame 100. Hereinafter, the space formed by the first inclined surface 221 of the second discharge rail 220 and the inclined surface of the connecting portion 130 is referred to as the first moving passage. This first movement passage may be formed along the outer periphery of the discharge cap 200.

The second discharge rail 220 may further include a second inclined surface 222 inclined toward the discharge opening 201 at a portion adjacent to the discharge opening 201 . Here, the average angle O1 formed between the second inclined surface 222 and the extension line of the first inclined surface 221 may be between 10° and 50°.

This second inclined surface 222 may be formed parallel to the inclined surface formed at the starting end 140S of the separation rib 140. Hereinafter, the space formed by the second inclined surface 222 of the second discharge rail 220 and the inclined surface of the separation rib 140 is referred to as the second movement passage.

The plurality of guide protrusions 230 are located on the boundary line of the first discharge rail 210 and the second discharge rail 220, and may be formed to protrude toward the first opening 100A of the first discharge rail 210. .

Such a plurality of guide protrusions 230 allow the inner and outer formulations loaded in the formulation guidance groove 340 to move along the first discharge rail 210 and the second discharge rail 220 to the discharge port 201. When adjacent, it can perform the function of separating the inner and outer formulations rather than overlapping each other.

As shown in (a) and (d) of FIGS. 8, the memory chip storage unit 10 may accommodate a memory chip 205 storing information about the formulation stored in the cartridge 70.

As shown in (a) and (c) of FIGS. 8, the first portion 201A where the first inclined surface 221 of the second discharge rail 220 and the vertical side of the discharge port 201 meet at the discharge port 201. ) may be formed lower than the height of the second portion 201B where the first inclined surface 221 of the second discharge rail 220 and the vertical side of the discharge port 201 meet.

Here, the first part 201A of the discharge port 201 is a part that meets before the outer formulation is discharged through the discharge port 201 when the rotor unit 300 rotates forward, and the second part of the discharge port 201 ( 201B) is the part where the formulation meets after it is discharged through the discharge port 201.

Accordingly, the outer formulation moved along the second inclined surface 222 of the second discharge rail 220 collides with the inner wall forming the second part 201B of the discharge port 201 in a diagonal direction and then naturally hits the discharge pipe ( 202), the phenomenon of the discharge port 201 being blocked by a plurality of formulations can be minimized even if the rotor unit 300 rotates at high speed.

FIG. 9 is a diagram for explaining an example of the rotor unit 300 in FIG. 5 in more detail, and FIG. 10 is a diagram for explaining a state in which the rotor, discharge cap 200, and frame 100 in FIG. 5 are combined. am.

Figure 9 (a) is a perspective view of the rotor unit 300 looking down from above, Figure 9 (b) is a view of the rotor part 300 from the outside of the formulation guidance groove 340, and Figure 9 (c) ) shows a cross-section of the rotor unit 300 along the line S3-S3 in FIG. 9, and (d) in FIG. 9 shows a plurality of formulations loaded into each formulation guide groove 340 of the rotor section 300. It shows an example.

Figures 10 (a) and (b) are diagrams for explaining the coupling relationship between the rotor unit 300 and the discharge cap 200, and Figure 10 (c) shows the rotor unit 300 and the discharge cap 200. In order to explain the connection relationship between the frame 100 and the frame 100, the frame 100 is shown along with a cross section along the line S4-S4 in (b) of FIG. 10.

As shown in FIG. 9, the rotor unit 300 includes a rotor cone 310, a first rotor rail 320, a second rotor rail 330, a formulation guide groove 340, and a drive shaft groove 301. can do.

9 and below, descriptions of content that overlaps with the above-described content regarding the formulation guide groove 340 and the drive shaft groove 301 will be omitted.

The rotor unit 300 may be formed in an overall circular shape, and the rotor cone 310 may be located at the center of the circular shape. The rotor cone 310 is located at the center of the rotor unit 300 and may protrude from a circular surface in the direction in which the cartridge 70 is located. For example, the rotor cone 310 may have a cone shape with a gentle slope.

The rotor cone 310, together with the inner wall 120 of the frame 100, can form the bottom surface of a space where a plurality of formulations are located, and can form a plurality of formulations to prevent the multiple formulations located within the frame 100 from sticking to each other. It can function to disperse.

For this purpose, the rotor cone 310 includes a first rotor cone portion 310A including a curved surface according to a cone shape and a second rotor cone portion 310B including a surface that is flatter than the curved surface. (310A) and the second rotor cone portion (310B) may be positioned alternately according to the rotation direction of the rotor cone (310).

Accordingly, the plurality of formulations located in contact with the rotor cone 310 are distributed in the normal direction of the rotor cone 310 by receiving force from the second rotor cone portion 310B when the rotor cone 310 rotates. You can.

In addition, by ensuring that the hardness is above the standard value (e.g., 2.4 kp), even when a plurality of formulations are attached in contact with each other, the formulation is formed due to the impact of the first and second rotor cone portions 310A and 310B of the rotor cone 310. This can be allowed to disperse apart.

At this time, the plurality of dosage forms may be impacted by the second rotor cone portion 310B. If the hardness of the plurality of formulations is less than the standard value (e.g., 2.4 kp), there is a high possibility that the formulations will be broken by the impact of the second rotor cone portion 310B. However, by ensuring that the formulation according to the present invention has a hardness above the standard value, breakage of the formulation can be minimized.

The first rotor rail 320 has a predetermined width and extends long along the outer periphery of the rotor cone 310, and the second rotor rail 330 has a step toward the bottom of the first rotor rail 320 and has a predetermined width. It may extend long along the outer periphery of the first rotor rail 320 with a determined width.

A plurality of formulations can be positioned in contact with the upper part of the rotor cone 310 and the upper part of the first rotor rail 320, but cannot be positioned in contact with the upper part of the second rotor rail 330. This will be explained with reference to (c) of FIG. 10.

In addition, as shown in FIG. 9, the outer periphery of each of the first rotor rail 320 and the second rotor rail 330 may have a downward width.

In the second rotor rail 330, the portion 340A adjacent to the formulation guidance groove 340 may be formed to have an inclination. For example, as shown in Figure 9 (b), when the rotor unit 300 rotates forward in the second rotor rail 330 on which the formulation guide groove 340 is formed, the lower part of the portion 340A in contact with the formulation has an inclined surface. It can be provided.

The formulation guidance groove 340 is located on the extension line of the second rotor cone portion 310B in a direction crossing the first rotor rail 320 and the second rotor rail 330, and the first rotor rail 320 and the second rotor rail 330 2 A portion of the rotor rail 330 may be provided in an open form.

Accordingly, portions of the first discharge rail 210 and the second discharge rail 220 located below the rotor unit 300 may be exposed at the portion where the formulation guide groove 340 is formed, as shown in FIG. 10 . In addition, when the rotor unit 300 rotates, a portion of each formulation guide groove 340 may overlap the discharge port 201 in the vertical direction (z), as shown in Figures 10 (a) and (b).

9 and 10 show an example where the number of formulation guide grooves 340 is three, but the present invention is not limited to this, and the number of formulation guide grooves 340 may be more or less than three. .

As shown in (d) of FIG. 9, in order to discharge the formulation, a plurality of formulations may be arranged in a row and loaded into the formulation guiding groove 340. To this end, as shown in FIG. 10, the formulation guiding groove 340 may have a first width W1 and a first length L1 in which a plurality of formulations can be arranged in a row.

As shown in Figures 10 (a) and (b), each of the dosage forms (B1, B2) may include a cylindrical dosage form or a spherical dosage form, and has a second width (W2) and a second length (L2). You can have it. In one example, the second width (W2) or second length (L2) of the dosage form may be between 3 and 7 mm.

Here, the second width (W2) and second length (L2) of the dosage form may be different from each other within a preset range as described above. For example, the ratio of the second length (L2) to the second width (W2) may be between 1:0.5 and 1:1.5.

The first width (W1) of the formulation guide groove 340 is formed to be larger than the second width (W2) or the second length (L2) of the formulation, and is a width that can accommodate one formulation in the direction of the first width (W1). You can have For example, the first width W1 may have a ratio between 1.1 and 1.5 times the second width W2 or the second length L2.

The first length L1 of the formulation guiding groove 340 is formed to be larger than the first width W1 of the formulation guiding groove 340, the second width W2 or the second length L2 of the formulation, and is formed with a plurality of It may have a length that allows the dosage forms to be arranged in a row and loaded. As an example, the first length L1 may have a ratio value between 1.5 and 2.5 times that of the first width W1. Additionally, the first length L1 may have a ratio between 1.5 and 2.5 times the second width W2 or the second length L2. The first length L1 is set to a range smaller than the second width W2 or twice the second length L2 between the end of the second rotor rail 330 and the outer wall 110 of the frame 100. It takes into account the shortcomings.

In addition, the first height (H1) from the upper surface of the first discharge rail 210 exposed by the formulation guidance groove 340 to the upper surface of the first rotor rail 320 is determined by the rotation of the rotor unit 300. When doing so, it may have a size that minimizes friction or collision between the dosage form loaded in the dosage form guide groove 340 and other dosage forms that are not loaded. To this end, the first height (H1) may have a ratio value between 0.8 and 1.2 times the second width (W2) or second length (L2) of the dosage form.

As shown in (c) of FIG. 10, the plurality of formulations are formed by the inner wall 120 of the frame 100, the rotor cone 310 of the rotor unit 300, and the first rotor rail 320. It can be located in space. At this time, the formulation cannot be located on the second rotor rail 330 of the rotor unit 300.

In this state, some of the plurality of formulations may be loaded into the inner portion of the formulation guidance groove 340 where the first discharge rail 210 is exposed.

Thereafter, as the rotor unit 300 rotates forward, the formulation may be moved to the outer portion of the formulation guidance groove 340 where the second discharge rail 220 is exposed.

Thereafter, the dosage form moved to the outer portion of the dosage form guidance groove 340 can move along the first movement passage formed along the second discharge rail 220 as the rotor unit 300 continues to rotate forward, and the dosage form moves along the first movement passage formed along the second discharge rail 220. When located on the discharge port 201, the discharge unit 80 can be discharged through the discharge port 201.

Hereinafter, the process by which the above-described discharge unit 80 discharges a plurality of formulations will be described in more detail.

Figures 11A to 11E are diagrams for explaining a process in which the discharge unit 80 discharges a formulation according to an example of the present invention.

In each of FIGS. 11A to 11D, (a) is a shape of the discharge cap 200 viewed from above, and (b) is an image of a portion of the frame 100 adjacent to the discharge port 201 cut away. In each of FIGS. 11A to 11E, the position of the formulation guidance groove 340 and the separation rib 140 are virtually displayed on the corresponding portion of the discharge cap 200.

As shown in FIG. 11A, a plurality of dosage forms may be arranged in a row in the dosage form guiding groove 340. Hereinafter, the dosage form located inside the dosage form guiding groove 340 is referred to as the first dosage form (B1), and the dosage form located outside the dosage form guiding groove 340 is referred to as the second dosage form (B2).

As the rotor unit 300 rotates forward with a plurality of formulations arranged in a row in the formulation guidance groove 340, the first formulation (B1) moves along the first discharge rail 210, and the second formulation (B2) ) can be moved along the first movement path formed by the second discharge rail 220 and the connection portion 130.

Thereafter, as shown in FIG. 11B, the rotor unit 300 continues to rotate forward, and the formulation guidance groove 340 passes through the plurality of guide protrusions 230 of the discharge cap 200, and the plurality of guide protrusions 230 ), the first dosage form (B1) can be separated to the inside, and the second dosage form (B2) can be separated to the outside.

Thereafter, as shown in (a) of FIG. 11C, the rotor unit 300 continues to rotate forward, and the dosage form guidance groove 340 passes under the separation rib 140 to form the first dosage form (B1) and the second dosage form. (B2) can be completely spaced apart spatially by the separation rib 140.

In addition, as shown in (b) of FIG. 11C, the second formulation (B2) is formed by the second inclined surface 222 of the second discharge rail 220 and the lower inclined surface of the separating rib 140. It can be forcibly moved in a diagonal direction toward the discharge pipe 202 along the moving passage.

Thereafter, when the rotor unit 300 continues to rotate forward, as shown in (a) of FIG. 11D, the second formulation (B2) moves inside the discharge port 201 and forms a diagonal line on the inner wall of the discharge port 201. It can naturally move downward along the discharge pipe 202 while colliding in that direction.

This second movement passage allows the formulation to move in a diagonal direction in the discharge pipe 202, preventing jamming of the discharge port 201 by a plurality of formulations even if the rotor unit 300 rotates at a relatively high speed. It can be prevented.

At this time, the first formulation (B1) located on the first discharge rail 210 in the formulation guidance groove 340 is separated by the separation rib 140, as shown in (b) and (c) of Figure 11D. Discharge toward the discharge pipe 202 may be blocked. To this end, the vertical gap (Dt) between the separation rib 140 and the upper surface of the first discharge rail 210 may be smaller than the second width (W2) or second length (L2) of the dosage form.

Thereafter, when the rotor unit 300 continues to rotate forward, as shown in FIG. 11E, at the point past the end 140E of the separation rib 140, the first dosage form B1 is moved to the outside of the dosage form guidance groove 340 by centrifugal force. is pushed out, and the third dosage form located near the dosage form guidance groove 340 may be newly loaded inside the dosage form guidance groove 340.

As described above, the formulation according to the present invention has an appropriate maximum width and maximum height, and the ratio of the maximum width and maximum height is formed in an appropriate range, so that it has a structure that can be easily discharged through the dispenser (1). .

In addition, the formulation used in the dispenser 1 of the present invention is (1) impacted by the second rotor cone portion 310B of the rotor portion 300 during the process of being discharged from the cartridge 70, and (2) When the rotor unit 300 rotates forward, the dosage form loaded in the dosage form guide groove 340 and the dosage form located at the top of the rotor unit 300 rub against or impact each other, and (3) are discharged through the second connection passage through the discharge port ( In the process of exiting through 201), it may receive a shock by hitting the inner wall of the discharge port 201.

However, the formulation according to the present invention has a hardness greater than the standard value, and thus it is possible to minimize or prevent breakage of the formulation even upon impact as described above.

So far, the present invention has been examined focusing on its preferred embodiments. A person skilled in the art to which the present invention pertains will understand that the present invention may be implemented in a modified form without departing from the essential characteristics of the present invention. Therefore, the disclosed embodiments should be considered from an illustrative rather than a restrictive perspective. The scope of the present invention is indicated in the claims, not the foregoing description, and all differences within the equivalent scope should be construed as being included in the present invention.

Claims (22)

A frame, a rotor unit rotatably coupled within the frame and having a dosage form guide groove into which the dosage form to be discharged to the outside is seated, and a rotor unit fixedly coupled to the frame at the bottom of the rotor unit and discharging the dosage form seated in the dosage form guide groove to the outside. In the dispenser including a discharge cap provided with a discharge port,
The formulation is
Main ingredient containing nutritional ingredients; and
Contains additives mixed with the main ingredient,
The formulation has a pillar shape,
The maximum width of the horizontal cross-section of the pillar shape is 3 mm to 7 mm,
It has a height in the vertical direction intersecting the horizontal direction, and the maximum height of the column shape is such that the ratio of the maximum height in the vertical direction to the maximum width in the horizontal direction is in the range of 1: 0.8 to 1: 1.2. has a height with a value,
The upper or lower surface of the pillar shape includes a curved surface having a predetermined radius of curvature with respect to the vertical direction, and the ratio of the radius of curvature to the maximum width of the horizontal cross section is between 1: 0.8 and 1: 1.8,
The hardness of the formulation is 2.4 kp to 20 kp,
The dispenser in which the formulation is used is
a cartridge storing the dosage form; and
a discharge unit that has the frame, the rotor unit, and the discharge cap to discharge the formulation from the cartridge, and is mounted on or removed from the dispenser while being coupled to one end of the cartridge;
It includes a receiving portion having a plurality of receiving grooves into which a cartridge portion in which the cartridge and the discharging unit are combined is inserted and mounted,
The frame is screwed to be separable from the cartridge,
The formulation guidance groove provided in the rotor unit is provided with a long opening from the inside to the outside, and has a width and length such that a plurality of the formulations are arranged in one line therein,
In the formulation, the error in the discharge amount from the dispenser is 10% of the target discharge amount due to the range of the maximum cross-sectional width, the ratio range of the maximum height in the vertical direction, the ratio range of the radius of curvature, and the range of hardness of the formulation. A dispenser having characteristics within %, wherein the error in the discharge amount is the difference between the target discharge amount and the actual discharge amount of the dispenser in which the formulation is stored.
delete delete delete According to paragraph 1,
A dispenser, characterized in that the disintegration time of the formulation is within 20 minutes.
delete delete delete According to paragraph 1,
A dispenser, characterized in that the main ingredient contains a water-soluble component.
According to paragraph 1,
The main ingredients are magnesium (MgO), vitamin D, vitamin C, vitamin B1, vitamin B2, niacin, pantothenic acid, vitamin B6, biotin, folic acid, vitamin B12, vitamin E, iron, chromium, molybdenum, selenium, zinc, iodine, A dispenser comprising at least one selected from the group consisting of manganese and copper.
According to paragraph 1,
A dispenser, wherein the main ingredient contains nutritional ingredients of herbal medicine.
According to paragraph 1,
The additive is a pharmaceutically acceptable substance for the main ingredient and is characterized in that it contains at least one selected from the group consisting of a bulky agent (BA), a disintegrant, a lubricant, and an anti-caking agent.
According to paragraph 1,
A dispenser, characterized in that the surface of the pillar shape is coated with a material other than the additive to increase the surface strength of the pillar shape.
According to paragraph 1,
A dispenser, characterized in that the cross-section of the column shape is square, pentagonal, hexagonal, octagonal, circular, or oval.
According to paragraph 1,
A dispenser, characterized in that a certain number of the formulations are discharged at a time by the dispenser.
delete According to clause 15,
The dispenser is equipped with a plurality of the cartridges,
A dispenser, wherein the dosage form is dispensed from each cartridge of the dispenser at a rate of between 3 and 7 units per second.
According to clause 15,
The dispenser is characterized in that 25 to 250 formulations are discharged from the dispenser at a time, and the discharge time for one time is between 1 second and 10 seconds.
delete delete delete delete